Reviewer's report

Title: Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis

Version: 2 Date: 24 January 2011

Reviewer: Leslie Citrome

Reviewer's report:

The authors have made all the requisite changes. Some minor points regarding language:

1. "This information was collected through a routine clinical interview by a psychiatrist every six months, and the relapse was defined comparatively to baseline characteristics of the patient. A complementary research was also realized on the medical record of the patient and also through an interview of the staff." could be rephrased as "This information was collected by routine clinical interview by a psychiatrist every six months, and relapse was defined using information regarding the baseline characteristics of the patient. Additional relevant information was obtained from the medical record and also through staff interview."

2. In their comments in response to a query, the authors state "No patient received a depot and oral antipsychotic." This is not consistent with the statement "22 patients in the polypharmacy group (31.9%) and 37 patients in the monotherapy group (32.5%) had a depot antipsychotic medication." Did the authors actually mean "No patient received a depot and its corresponding oral antipsychotic."?

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

Leslie Citrome, is a consultant for, has received honoraria from, or has conducted clinical research supported by the following: Abbott Laboratories, AstraZeneca Pharmaceuticals, Avanir Pharmaceuticals, Azur Pharma Inc, Barr Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, Forest Research Institute, GlaxoSmithKline, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Merck, Novartis, Orexigen Therapeutics, Pfizer Inc, Sunovion, Valeant
Pharmaceuticals and Vanda Pharmaceuticals.